Furthermore, other families with a high likelihood of a mutation do not harbor a known pathogenic variant, demonstrating that much of the genetic contribution to breast cancer development has yet to be characterized; demonstrating the importance of multi‐gene panel testing beyond just BRCA1/2 [10, 11, 12, 13]. The gene discussed is BRCA1; the disease is breast cancer.